DK1082341T3 - Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer - Google Patents

Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer

Info

Publication number
DK1082341T3
DK1082341T3 DK99927164.6T DK99927164T DK1082341T3 DK 1082341 T3 DK1082341 T3 DK 1082341T3 DK 99927164 T DK99927164 T DK 99927164T DK 1082341 T3 DK1082341 T3 DK 1082341T3
Authority
DK
Denmark
Prior art keywords
prostate
tmprss2
diagnosis
colon cancer
treatment
Prior art date
Application number
DK99927164.6T
Other languages
Danish (da)
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Kahan Leong
Arthur B Raitano
Douglas C Saffran
Stephen Chappell Mitchell
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DK1082341T3 publication Critical patent/DK1082341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99927164.6T 1998-06-01 1999-06-01 Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer DK1082341T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US9147498P 1998-06-29 1998-06-29
US12952199P 1999-04-14 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Publications (1)

Publication Number Publication Date
DK1082341T3 true DK1082341T3 (da) 2011-03-28

Family

ID=27375711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99927164.6T DK1082341T3 (da) 1998-06-01 1999-06-01 Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer

Country Status (12)

Country Link
US (1) US20060275304A1 (enExample)
EP (1) EP1082341B1 (enExample)
JP (2) JP2002517185A (enExample)
AT (1) ATE490977T1 (enExample)
AU (2) AU773187B2 (enExample)
CA (1) CA2329137C (enExample)
CY (1) CY1111906T1 (enExample)
DE (1) DE69943020D1 (enExample)
DK (1) DK1082341T3 (enExample)
IL (1) IL139988A0 (enExample)
PT (1) PT1082341E (enExample)
WO (1) WO1999062942A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU774436B2 (en) 1999-08-12 2004-06-24 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US20020040127A1 (en) * 2000-06-09 2002-04-04 Yuqiu Jiang Compositions and methods for the therapy and diagnosis of colon cancer
EP1294903B1 (en) 2000-06-13 2008-05-07 Bayer HealthCare AG Regulation of human transmembrane serine protease
EP2075582A3 (en) * 2000-07-12 2010-01-06 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2612870A1 (en) 2005-09-12 2013-07-10 The Regents of the University of Michigan Recurrent gene fusions in prostate cancer
WO2008119767A2 (en) * 2007-03-30 2008-10-09 Oryzon Genomics, S. A. Method of nucleic acid analysis.
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CN102712953A (zh) 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
BR112014018005B1 (pt) * 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
JP3149185B2 (ja) * 1993-01-15 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド エンテロキナーゼのクローニングおよび使用方法
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1195851C (zh) * 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
DE69831222T2 (de) * 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6166194A (en) * 1998-06-29 2000-12-26 Myriad Genetics, Inc. TMPRSS2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
JP2002517185A (ja) 2002-06-18
CY1111906T1 (el) 2015-11-04
WO1999062942A2 (en) 1999-12-09
AU4413699A (en) 1999-12-20
ATE490977T1 (de) 2010-12-15
EP1082341B1 (en) 2010-12-08
PT1082341E (pt) 2011-02-15
EP1082341A2 (en) 2001-03-14
AU2004202306A1 (en) 2004-06-24
CA2329137A1 (en) 1999-12-09
US20060275304A1 (en) 2006-12-07
IL139988A0 (en) 2002-02-10
CA2329137C (en) 2011-09-20
JP2009148265A (ja) 2009-07-09
AU2004202306B2 (en) 2007-05-24
WO1999062942A3 (en) 2000-06-02
AU773187B2 (en) 2004-05-20
AU2004202306C1 (en) 2008-05-01
DE69943020D1 (de) 2011-01-20

Similar Documents

Publication Publication Date Title
CY1111906T1 (el) Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
AU1726199A (en) Metastatic cancer regulated gene
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
DK0912738T3 (da) Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
ATE354656T1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
DK0922223T3 (da) Fremgangsmåde til prognosticering af cancer
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DK0833948T3 (da) Tyktarmspecifikt gen og protein
Gallee et al. Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC‐82
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
Barra et al. Primary structure of human copper-zinc superoxide dismutase. Cysteine-and tryptophan—Containing peptides
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
TR200003345T2 (tr) Moraxella Catarrhalıs'in bileşikleri
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
FR2795414B1 (fr) Polypeptide icbp90 et ses fragments et polynucleotides codant lesdits polypeptides et applications au diagnostic et au traitement du cancer
ATE321885T1 (de) Modulation der neurokrinen differenzierung durch protein 25.1
HUP0001270A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer